TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age between 45 and 75 years~* Diagnosis of diabetes mellitus made within the two years preceding the date of observation (new onset diabetes)~* Adherence to the study documented the voluntary signing of an informed consent~* Availability to follow a telephone follow-up~Exclusion Criteria:~* Remote medical history (\> 2 years) positive for diabetes mellitus~* Previous history of malignancy~* Pregnancy~* Renal Failure~* Documented diabetic microangiopathy~* Sepsis

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- High AM (Type: None): Newly diagnosed diabetic patients with high Adrenomedullin serum levels
- Low AM (Type: None): Newly diagnosed diabetic patients with low Adrenomedullin serum levels

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Humidity Therapy for Spontaneously Breathing Tracheostomy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Greater than eighteen years old~* Tracheotomized less than or equal to two weeks before entry into the study~* Spontaneously breathing~Exclusion Criteria~* Less than eighteen years old~* Tracheotomy performed more than two weeks prior to enrolment in the study~* Mechanically ventilated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heated humidification (HH) (Type: EXPERIMENTAL): Addition of water vapor (molecular water) to the inspired gas of spontaneously breathing tracheostomy patients.
- Cool bland aerosol (LVN) (Type: ACTIVE_COMPARATOR): Addition of particulate water to the inspired gas of spontaneously breathing tracheostomy patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female age ≥18 years~* Patient is scheduled to undego orthotopic liver transplantation (OLT)~* Patient has a natural MAYO End-Stage Liver Disease (MELD) score of 15-40~* Patient is willing to give voluntary written informed consent before any study- related procedure is to be performed that is not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudicing future medical care~Exclusion Criteria:~* Patient has a history of severe hypersensitivity reaction to plasma-derived products or to any excipient of the investigational product~* Patient is known to be IgA deficient with documented antibodies against IgA~* Patient is a planned recipient for a living donor OLT~* Patient has a severe deficiency of Protein S~* Patient is currently participating in an interventional clinical study or has participated in one within 30 days of the date of their OLT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octaplas™ (Type: None): Patients treated with Octaplas™ infusion solution for IV administration as prescribed by their treating physician.
- Plasma (Type: None): Patients treated with regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: User Satisfaction When Catheterizing With Hydrophilic Urinary Catheters From a More Sustainable Manufacturing Process.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~For inclusion in the study, subjects must fulfil all of the following criteria:~1. Provision of informed consent i.e. subject must be able to understand and sign the Informed Consent Form~2. Aged 18 years and over, both gender~3. Bladder dysfunction, all diagnosis practicing IC at least 2 times daily~4. Using catheters in the sizes available in the investigation (15 cm, CH 12 or 40 cm CH 12/14, Nelaton tip)~5. Experienced users of IC defined as a minimum of 4 weeks on therapy prior investigation start~6. Adults able to read, write and understand information given to them regarding the investigation~Exclusion Criteria:~Any of the following is regarded as a criterion for exclusion from the study:~1. Ongoing, symptomatic UTI at enrolment as judged by investigator. The definition of UTI, is a positive urine culture of ≥103 CFU/ml of ≥1 bacterial species and presence of symptoms or signs compatible with UTI with no other identified source of infection.~2. Known urethral stricture which, in the opinion of the investigator, could influence the subject's evaluation of the catheters.~3. Involvement in the planning and conduct of the investigation (applies to both Wellspect/site staff).~4. Previous enrolment in the present investigation.~5. Simultaneous participation in another clinical investigation that may impact the primary endpoint.~6. Expected or severe non-compliance to the CIP as judged by the investigator and/or Wellspect.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LoFric® OrigoTM or LoFric® SenseTM (Type: EXPERIMENTAL): Hydrophilic male (LoFric Origo) and female (LoFric Sense) urinary catheters for single use. Target subject population are subjects suffering from bladder voiding dysfunction and are experienced in intermittent catheterization (IC).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patient (≥ 18 years)~* patient hospitalized~* patient receives systemic antibiotic treatment~* patient contractually capable~* patient able to follow study procedures~* informed consent of patient~Exclusion Criteria:~* allergy against yeast and/or Perenterol® forte und/oder placebos containing Saccharomyces cerevisiae HANSEN CBS 5926, lactose-monohydrate, magnesium stearate, gelatine, sodium dodecyl sulfate, titan dioxide, microcrystalline cellulose.~* central venous catheter~* immunosuppression~* diarrhoea and/or chronic diarrhoea~* regular intake of Perenterol®, Perenterol® forte oder Yomogi® in the last seven days before the start of the study~* systemic antimycotic treatment~* systemic antibiotic treatment within the last 6 weeks~* no protection against conception, pregnancy, or lactation~* simultaneous participation in other clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saccharomyces boulardii (Type: ACTIVE_COMPARATOR): Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
- Microcristallin cellulose (Type: PLACEBO_COMPARATOR): Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Midazolam Effect in Children Undergoing Voiding Cystourethrogram (VCUG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 2-6 years~* Toilet trained~* English speaking~* Already scheduled for VCUG~Exclusion Criteria:~* Allergic to midazolam~* Active UTI~* Known urethral stricture~* Known urethral reconstruction~* Has history of abnormal sensation in pelvic area~* Has history of sexual abuse~* Has severe developmental delay~* Has diagnosis of anxiety disorders

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Versed (Type: EXPERIMENTAL): Both patients who are VCUG naive and patients who have had a previous VCUG are given oral midazolam prior to undergoing the VCUG.
- Placebo (Type: PLACEBO_COMPARATOR): Both patients who are VCUG naive and patients who have had a previous VCUG are given an oral placebo prior to undergoing the VCUG.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of REnal Denervation for Resistant Hypertension on Exercise Diastolic Function and Regression of Atherosclerosis and the Evaluation of NEW Methods Predicting A successfuL Renal Sympathetic Denervation (RENEWAL-EXERCISE, -REGRESS, and -PREDICT Trial From RENEWAL RDN Registry)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 20-85 years with resistant hypertension defined as systolic BP\>140 mmHg (\>130 mmHg for diabetes) or diastolic BP\>90mmHg (\>80 mmHg for diabetes) despite adequate administration of 3 or more different classes of anti-hypertensive medications including diuretics with good adherence and adequate treatment regimen.~* All agents should be prescribed at optimal dose amounts. BP was based on an average of 3 office BP readings measured according to the general guidelines. Patients are adhering to a stable drug regimen including 3 or more antihypertensive medications (with no changes for a minimum of 2 weeks prior to enrollment).~* Patients provided with the written, informed consent to participate in this study~Exclusion Criteria:~* Hemodynamically or anatomically significant renal artery abnormalities, main renal arteries \< 4 mm in diameter or \< 20 mm in length, or.prior renal artery intervention~* Estimated glomerular filtration rate (eGFR) of \< 30mL/min/1.73m2, using the MDRD calculation~* Hemodynamically significant valvular heart disease~* History of congestive heart failure with reduce LV ejection fraction of less than 35%~* CVA in the prior 3 months~* ST-segment elevation MI within 48 hours~* Scheduled or planned surgery or cardiovascular intervention in the next 6 months.~* Patients with chronic debilitating disease with life expectancy of less than 1 year~* Patients taking hormone replace treatment and/or oral contraceptives; pregnant, nursing or planning to be pregnant~* Chronic liver cirrhosis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- RD group (Type: EXPERIMENTAL): Renal denervation group
- Control group (Type: ACTIVE_COMPARATOR): Control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary CNS lymphoma based on 1 of the following:~  * Histologically confirmed non-Hodgkin's B-cell lymphoma by brain biopsy or resection~ * Positive cerebrospinal fluid (CSF) cytology or immunohistochemical diagnosis of CSF monoclonality with or without measurable intracranial disease~ * Histologically confirmed vitreal lymphoma with measurable intracranial tumor~* CD20 positive by brain biopsy~* Measurable (greater than 1 cm in diameter) tumor by CT scan or MRI~* Progressed during first-line chemotherapy and/or radiotherapy OR relapsed after initial successful treatment~* No systemic lymphoma by CT scan of the chest, abdomen, and pelvis with contrast~* No leptomeningeal lymphoma by lumbar puncture for CNS cytology/flow cytometry~* No ocular lymphoma by slit lamp examination~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 9.0 g/dL~Hepatic~* Bilirubin less than 1.5 mg/dL~* Transaminases less than 4 times upper limit of normal~Renal~* Creatinine less than 1.5 mg/dL~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 1 year after study participation~* HIV negative~* Mini mental status examination score at least 15~* No concurrent serious infection~* No other medical illness that would preclude study treatment~* No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 90 days since prior biologic therapy~* No prior rituximab~* No concurrent prophylactic growth factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])~Chemotherapy~* See Disease Characteristics~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* At least 3 months since prior radiotherapy~Surgery~* Not specified~Other~* Recovered from prior therapy~* More than 90 days since prior investigational drugs~* More than 90 days since prior use of a therapeutic device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab monotherapy (Type: EXPERIMENTAL): Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* age 40-80 years~* stable dose of ≥ 1500 mg metformin or maximal tolerated dose of metformin for \> 6 weeks~* HbA1c ≥ 7 % - ≤ 9.0% for age \< 65 years and ≥ 7.5 % - ≤ 9.0% for age ≥ 65 years~* able and trained to perform SMBG~* the informed consent form must be signed before any study specific tests or procedures are done~* ability to understand and follow study-related instructions~Exclusion Criteria:~* Type 1 diabetes~* previous treatment with insulin, GLP1 analogues and SU in \< 6 month~* HbA1c \> 9 % or FPG \> 15 mmol/l at randomization~* renal impairment with eGFR \< 60 ml/min~* medical history of severe hypoglycemia defined as necessity of medical assistance in \< 1 year~* major cardiovascular event (MACE) in medical history \< 6 months~* preexisting atrial fibrillation, , AV block ≥II degree, pace-maker, implanted defibrillator~* major cardiovascular event in medical history \< 6 months~* heart failure NYHA ≥ III~* contraindications to glimepiride and sitagliptin or to any excipients according to product information~* severe cognitive deficits~* Patients who are disable to read and understand informative aspects of the trial~* Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s)~* Inability to comply with study procedures~* Pregnant or breast-feeding woman and woman without adequate method of contraception

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)
- Arm B (Type: ACTIVE_COMPARATOR): Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: pancreatic solid lesion presence (pancreatic adenocarcinoma and neuroendocrine tumors) resected during pancreatic surgery -~Exclusion Criteria: no signature on informed consent~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- resected PDAC without neoadjuvant chemotherapy treatment (Type: EXPERIMENTAL): Subgroup A: 10 W (5 patients) Subgroup B: 30 W (5 patients) Subgroup C: 50 W (5 patients)
- resected PDAC with neoadjuvant chemotherapy treatment (Type: EXPERIMENTAL): Subgroup A: 10 W (5 patients) Subgroup B: 30 W (5 patients) Subgroup C: 50 W (5 patients)
- resected neuroendocrine tumors (Type: EXPERIMENTAL): Subgroup A: 10 W (5 patients) Subgroup B: 30 W (5 patients) Subgroup C: 50 W (5 patients)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Isoflavones in Treating Women Who Have Breast Cancer and Are Planning to Undergo Mastectomy or Lumpectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Undergoing breast biopsy for any stage breast cancer~  * No excisional biopsy~ * At least one core biopsy block must contain carcinoma~* Definitive surgery (mastectomy or lumpectomy) planned for 2-4 weeks after registration to this study~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Female~Menopausal status:~* Premenopausal~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* No known prior hepatic disease~Renal:~* No known prior renal disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective non-hormonal contraception~* No other prior malignancy except nonmelanoma skin cancer~* No known prior thyroid disease~* No adherence to vegan diet or other special dietary requirements that would preclude study participation~* No allergy to study agent~* No obesity (body mass index greater than 32)~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* No concurrent birth control pills or other hormonal therapy~* No concurrent thyroid hormone replacement medications~Radiotherapy:~* Not specified~Surgery:~* See Disease Characteristics~Other:~* More than 30 days since prior antibiotics~* More than 4 weeks since prior soy products~* No routine consumption of greater than 40 mg of soy/day~* No other concurrent nutritional supplements, including modular supplements of other isoflavones

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Soy protein isolate (Type: EXPERIMENTAL): Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure.
- Placebo (Type: PLACEBO_COMPARATOR): Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral placebo twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Capable and willing to provide consent~2. history of clinically-diagnosed retinal microvascular diseases, including but not limited to diabetic retinopathy, retinal vein occlusion, idiopathic macular telangiectasias, hypertensive retinopathy, and age-related macular degeneration~3. At least 18 years of age~Exclusion Criteria:~1. Unable or unwilling to give consent~2. Under 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- retinal vascular occlusion arm (Type: OTHER): Patients with existing retinal microvascular disease will undergo imaging.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues